Patents by Inventor Lei Ling

Lei Ling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Treatment of Metabolic Disorders and Diseases
    Publication number: 20210169983
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: August 10, 2020
    Publication date: June 10, 2021
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS
    Publication number: 20200390859
    Abstract: Provided herein are variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). In some embodiments, these variants and fusions modulate bile acid homeostasis, and are useful in treatment of bile acid related and associated disorders. In some embodiments, these variants and fusions have glucose lowering activity, and are useful in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: June 30, 2020
    Publication date: December 17, 2020
    Inventors: Lei Ling, Jian Luo, Hui Tian
  • Combination Therapy for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases
    Publication number: 20200390858
    Abstract: Provided herein are methods of modulating bile acid homeostasis or treating a bile acid-related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile acid-related or associated disorder.
    Type: Application
    Filed: April 16, 2020
    Publication date: December 17, 2020
    Inventors: Alexander Mark DePaoli, Lei Ling
  • Ligand Assisted Chromatography for Metal Ion Separation
    Publication number: 20200308668
    Abstract: Presented herein is a ligand-assisted elution chromatography process for the separation of metal ions using a sorbent. In particular, the present invention discloses a process of two sets of column system in combination with two sets of eluting ligand solutions to prepare substantially pure rare earth elements, wherein the first set of column comprises strong acid cation exchange resins and the second set of chromatographic columns comprises hydrous polyvalent metal oxide selected from the group consisting of TiO2, ZrO2, or SnO2 and wherein ligand of said second ligand solution coordinates with said hydrous polyvalent metal oxide.
    Type: Application
    Filed: December 11, 2019
    Publication date: October 1, 2020
    Inventors: Nien-Hwa Linda Wang, Lei Ling
  • Methods of using compositions comprising variants and fusions of FGF 19 polypeptides for treating diabetes
    Patent number: 10758590
    Abstract: The invention relates to methods of using variants and fusions of fibroblast growth factor 19 (FGF19) for treating diabetes.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: September 1, 2020
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Methods of using variants of FGF19 polypeptides for the treatment of pruritus
    Patent number: 10744185
    Abstract: Provided herein are variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FG-F19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). In some embodiments, these variants and fusions modulate bile acid homeostasis, and are useful in treatment of bile acid related and associated disorders. In some embodiments, these variants and fusions have glucose lowering activity, and are useful in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: August 18, 2020
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo, Hui Tian
  • METHODS AND USES FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES
    Publication number: 20200197489
    Abstract: Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.
    Type: Application
    Filed: October 11, 2019
    Publication date: June 25, 2020
    Inventors: Lei LING, Hui TIAN
  • METHODS OF USING VARIANTS OF FGF19 POLYPEPTIDES FOR THE TREATMENT OF CANCER
    Publication number: 20200164035
    Abstract: Models useful in determining whether fibroblast growth factor 19 variant polypeptides having glucose-lowering activity and/or anti-obesity activity also exhibit favorable oncology-related profiles, and methods and uses associated therewith. Also provided are methods of antagonizing the oncogenic activity of FGF19 in a subject and, in certain embodiments, methods of preventing or treating a disease, disorder or condition, such as a FGF19-dependent disease, disorder or condition, or a symptom thereof.
    Type: Application
    Filed: June 26, 2019
    Publication date: May 28, 2020
    Inventor: Lei Ling
  • Ligand assisted chromatography for metal ion separation
    Patent number: 10597751
    Abstract: Presented herein is a ligand-assisted elution chromatography process for the separation of metal ions using a sorbent. In particular, the present invention discloses a process of two sets of column system in combination with two sets of eluting ligand solutions to prepare substantially pure rare earth elements, wherein the first set of column comprises strong acid cation exchange resins and the second set of chromatographic columns comprises hydrous polyvalent metal oxide selected from the group consisting of TiO2, ZrO2, or SnO2 and wherein ligand of said second ligand solution coordinates with said hydrous polyvalent metal oxide.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: March 24, 2020
    Assignee: Purdue Research Foundation
    Inventors: Nien-Hwa Linda Wang, Lei Ling
  • Methods and Compositions for the Treatment of Metabolic Disorders and Diseases
    Publication number: 20200054714
    Abstract: Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: August 6, 2019
    Publication date: February 20, 2020
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
    Patent number: 10456449
    Abstract: Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: October 29, 2019
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Hui Tian
  • METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS
    Publication number: 20190307847
    Abstract: Provided herein are variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). In some embodiments, these variants and fusions modulate bile acid homeostasis, and are useful in treatment of bile acid related and associated disorders. In some embodiments, these variants and fusions have glucose lowering activity, and are useful in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: August 28, 2017
    Publication date: October 10, 2019
    Inventors: Lei Ling, Hui Tian
  • Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject
    Patent number: 10413590
    Abstract: The invention relates to methods of using variants of fibroblast growth factor 19 (FGF19) for reducing body mass in a subject.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: September 17, 2019
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
    Patent number: 10398758
    Abstract: Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: September 3, 2019
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Methods of using variants of FGF19 polypeptides for the treatment of cancer
    Patent number: 10369199
    Abstract: Provided are methods of antagonizing the oncogenic activity of FGF19 in a subject. Also provided are methods of treating a FGF19-dependent cancer or tumor, or a symptom thereof in a subject.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: August 6, 2019
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventor: Lei Ling
  • METHODS OF TREATING FIBROBLAST GROWTH FACTOR 19-MEDIATED CANCERS AND TUMORS
    Publication number: 20190194337
    Abstract: Provided are methods of treating a FGF19-mediated cancer or tumor in a subject by administering to the subject an anti-IL-6 antibody or an anti-IL-6 receptor antibody or an inhibitor of STAT3/JAK signaling pathway, and pharmaceutical compositions relating thereto.
    Type: Application
    Filed: August 25, 2017
    Publication date: June 27, 2019
    Inventors: Lei Ling, Hui Tian
  • Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Cirrhosis
    Publication number: 20190175693
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: February 21, 2019
    Publication date: June 13, 2019
    Inventors: Lei Ling, Jian Luo
  • Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Liver Fibrosis
    Publication number: 20190175694
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: February 21, 2019
    Publication date: June 13, 2019
    Inventors: Lei Ling, Jian Luo
  • Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Nonalcoholic Fatty Liver Disease
    Publication number: 20190175692
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: February 21, 2019
    Publication date: June 13, 2019
    Inventors: Lei Ling, Jian Luo
  • Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Modulating Bile Acid Homeostasis in a Subject Having Liver Fibrosis
    Publication number: 20190175696
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: February 21, 2019
    Publication date: June 13, 2019
    Inventors: Lei Ling, Jian Luo